<DOC>
	<DOCNO>NCT02131259</DOCNO>
	<brief_summary>In Japan , post-approval execution post marketing surveillance ( PMS ) request Japanese Pharmaceutical Affairs Law ( J-PAL ) order accumulate safety efficacy data reexamination . Reexamination period define J-PAL . Eight year approval new substance , result PMS need submit part reexamination dossier Japanese regulatory authority , Ministry Health , Labour Welfare ( MHLW ) .</brief_summary>
	<brief_title>Long-term Observation PMS Afatinib</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Inclusion criterion : Patients EGFR mutationpositive inoperable recurrent NSCLC include . Exclusion criterion : None</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>